FDA tentatively approves first generic of twice-yearly HIV prevention shot

Key Facts

The US FDA has tentatively approved the first generic copy of lenacapavir, a shot given twice a year to prevent HIV.
Dr.
Reddy’s Laboratories is cleared to supply it for 120 low- and middle-income countries under a voluntary license from Gilead, maker of the brand drug Yeztugo, at an expected cost of about $40 per person per year. That approval does not allow commercial sales of the generic in the United States while Gilead’s patents remain in force.

How the views differ

State media, independent media and top voices on X

Two shots a year, at a program price near $40, can make strong HIV prevention realistic for people who will not stay on a daily pill.

global-health advocates focused on HIV prevention in poorer countries

A daily prevention pill asks someone to remember a medicine for a disease they do not have.

Many people stop.

Supporters say two injections a year, described as almost completely protective, remove that daily demand. The chain they point to is practical: Gilead’s voluntary license covers 120 lower-income countries, tentative FDA approval lets US government buyers procure the generic, and first supplies are expected by the end of 2026, with wider availability in 2027. For a person in one of those countries, that can mean long-acting protection at about $40 a year instead of a rich-country list price, if the shipments arrive as planned.

technology.org (Ind.)
contagionlive.com (Ind.)
statnews.com (Ind.)
eatg.org (Ind.)
poz.com (Ind.)

The cheap generic is real progress for licensed countries, and it also shows how long people outside that license may wait.

equity critics who argue patents and voluntary licenses still ration new medicines

These critics do not call the lower-income deal a failure.

They say a new drug changes lives only where people can get it, and this approval draws that line in law.

Tentative approval is permission for US government procurement under the license. It is not permission to sell the generic in US pharmacies. Patents on the brand are cited out to about 2040, so a cheap copy made for 120 countries does not become the US product. For someone in the United States, the chain runs the other way: the science is approved, a low-cost version is cleared for elsewhere, commercial sale at home stays blocked, and prevention still sits next to a list price of about $28,218 a year unless insurance or aid covers it. Speed abroad and a long exclusive period at home are, on this reading, the same agreement.

poz.com (Ind.)
statnews.com (Ind.)
technology.org (Ind.)

Most likely true

The core event is consistently reported by independent outlets and a Unitaid joint release: tentative FDA approval for Dr. Reddy’s generic lenacapavir, aimed at 120 low- and middle-income countries under Gilead’s voluntary license, with an expected price near $40 a year, US commercial sales still blocked, final patents cited to about 2040, and a US brand list price around $28,218. The June 2025 brand approval and the late-2026 / 2027 supply window are reported the same way.

Grey areas. Ask to dive deeper

Grok checks every side again and answers with sources.

Coverage

5 sources

Independent 5

How the views differ

Grey areas. Ask to dive deeper

Coverage

All sources